33.79
-0.32 (-0.94%)
| Previous Close | 34.11 |
| Open | 34.50 |
| Volume | 2,877,224 |
| Avg. Volume (3M) | 2,278,945 |
| Market Cap | 6,385,972,224 |
| Price / Sales | 27.09 |
| 52 Weeks Range | |
| Earnings Date | 20 Feb 2025 - 24 Feb 2025 |
| Profit Margin | -241.44% |
| Operating Margin (TTM) | -3,762.90% |
| Diluted EPS (TTM) | -2.88 |
| Quarterly Revenue Growth (YOY) | 237.10% |
| Current Ratio (MRQ) | 4.67 |
| Operating Cash Flow (TTM) | -520.73 M |
| Levered Free Cash Flow (TTM) | -288.27 M |
| Return on Assets (TTM) | -47.83% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | BridgeBio Pharma, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 1.00 |
|
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 5.41% |
| % Held by Institutions | 91.10% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 95.00 (Cantor Fitzgerald, 181.15%) | Buy |
| Median | 50.00 (47.97%) | |
| Low | 49.00 (Citigroup, 45.01%) | Buy |
| 49.00 (HC Wainwright & Co., 45.01%) | Buy | |
| Average | 59.00 (74.61%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 33.98 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 21 Feb 2025 | 95.00 (181.15%) | Buy | 36.85 |
| Citigroup | 21 Feb 2025 | 49.00 (45.01%) | Buy | 36.85 |
| Scotiabank | 21 Feb 2025 | 52.00 (53.89%) | Buy | 36.85 |
| 12 Feb 2025 | 49.00 (45.01%) | Buy | 31.95 | |
| HC Wainwright & Co. | 13 Feb 2025 | 49.00 (45.01%) | Buy | 31.56 |
| Evercore ISI Group | 23 Dec 2024 | 50.00 (47.97%) | Buy | 27.77 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |